As demonstrated in Figure 2(b), higher SNHG12 expression level indicated unfavorable RFS in prostate cancer and hepatocellular carcinoma (HR = 1.71, 95%CI 1.05–2.78, p < 0.05). Here, SNHG12 is linked to hepatocellular carcinoma.